Glucocorticoid Therapy increases the cardiovascular Risk in RA Patients

被引：0
|
作者：
Di Lellis, Maddalena Angela
机构：
来源：
AKTUELLE RHEUMATOLOGIE | 2024年 / 49卷 / 04期
关键词：
D O I：
10.1055/a-2246-4107
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The risk of cardiovascular events (CVE) in RA patients is increased by the use of glucocorticoids. Whether there is a threshold dose and maximum duration of corticoid use beyond which the CVE rate is increased is controversial. So et al. investigated the time-varying effect of glucocorticoids and their dose on the risk of major adverse cardiovascular events (MACE) in patients with RA.
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Cinacalcet therapy and cardiovascular risk in hemodialysis patients
    Zelaznicka, Marzena
    Kocelak, Piotr
    Glinianowicz, Magdalena Olszanecka
    Chudek, Jerzy
    POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ, 2012, 66 : 722 - 729
  • [32] Cardiovascular and metabolic impact of glucocorticoid substitution therapy in patients with Addison's disease
    Ben Salah, Dhoha
    Charfi, Nadia
    Elleuch, Mouna
    Kacem, Faten Hadj
    Rekik, Nabila
    Mnif, Mouna
    Mnif, Fatma
    Abid, Mohamed
    PAN AFRICAN MEDICAL JOURNAL, 2018, 30
  • [33] ADMA increases cardiovascular risk
    不详
    TRAC-TRENDS IN ANALYTICAL CHEMISTRY, 2002, 21 (03) : VII - VIII
  • [34] The modulation of corticosteroid metabolism by hydrocortisone therapy in patients with hypopituitarism increases tissue glucocorticoid exposure
    Sherlock, Mark
    Behan, Lucy Ann
    Hannon, Mark J.
    Alonso, Aurora Aragon
    Thompson, Christopher J.
    Murray, Robert D.
    Crabtree, Nicola
    Hughes, Beverly A.
    Arlt, Wiebke
    Agha, Amar
    Toogood, Andrew A.
    Stewart, Paul M.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2015, 173 (05) : 583 - 593
  • [35] Cardiovascular and Metabolic Impact of Glucocorticoid Replacement Therapy
    Johannsson, Gudmundur
    Ragnarsson, Oskar
    CARDIOVASCULAR ISSUES IN ENDOCRINOLOGY, 2014, 43 : 33 - 44
  • [36] Alendronate increases bone mass in patients receiving glucocorticoid therapy for pulmonary diseases.
    McClung, M
    Yanover, M
    Menkes, CJ
    Rodriguez-Portales, JA
    Czachur, M
    Carofano, W
    Malice, MP
    Daifotis, AG
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1998, 101 (01) : S4 - S4
  • [37] Variation among cardiovascular risk calculators in relative risk increases with identical risk factor increases Cardiovascular Disorders
    Allan G.M.
    Nouri F.
    Korownyk C.
    Kolber M.R.
    Vandermeer B.
    McCormack J.
    BMC Research Notes, 8 (1)
  • [38] MAJOR ADVERSE CARDIOVASCULAR EVENTS: RISK FACTORS IN PATIENTS WITH RA TREATED WITH TOFACITINIB
    Charles-Schoeman, C.
    Valdez, H.
    Soma, K.
    Hwang, L.
    DeMasi, R.
    Boy, M.
    McInnes, I. B.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1034 - 1035
  • [39] Major Adverse Cardiovascular Events: Risk Factors in Patients with RA Treated with Tofacitinib
    Charles-Schoeman, Christina
    Valdez, Hernan
    Soma, Koshika
    Hwang, Lie-Ju
    DeMasi, Ryan
    Boy, Mary
    McInnes, Iain B.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [40] A MODEL FOR QUANTIFYING THE EFFECT OF INFLAMMATION ON CARDIOVASCULAR DISEASE RISK PREDICTION IN RA PATIENTS
    Ben-Shachar, R.
    Flake, D.
    Bamford, R.
    Mabey, B.
    Sasso, E.
    Curtis, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 600 - 601
12345